Literature DB >> 22041175

Design, synthesis and biological activity of original pyrazolo-pyrido-diazepine, -pyrazine and -oxazine dione derivatives as novel dual Nox4/Nox1 inhibitors.

Francesca Gaggini1, Benoît Laleu, Mike Orchard, Laetitia Fioraso-Cartier, Laurène Cagnon, Sophie Houngninou-Molango, Angelo Gradia, Guillaume Duboux, Cédric Merlot, Freddy Heitz, Cédric Szyndralewiez, Patrick Page.   

Abstract

Pyrazolo-pyrido-diazepine, -pyrazine and -oxazine dione derivatives are new chemical entities with good and attractive druglikeness properties. A series of pyrazolo-pyrido-diazepine dione analogs demonstrated to be particularly amenable to lead optimization through a couple of cycles in order to improve specificity for isoforms Nox4 and Nox1 and had excellent pharmacokinetic parameters by oral route. Several molecules such as compound 7c proved to be highly potent in in vitro assays on human lung fibroblasts differentiation as well as in curative murine models of bleomycin-induced pulmonary fibrosis with superior efficiency over Pirfenidone. Pyrazolo-pyrido-diazepine dione derivatives targeting Nox4 and Nox1 isoforms appear highly promising therapeutics for the treatment of idiopathic pulmonary fibrosis.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22041175     DOI: 10.1016/j.bmc.2011.10.016

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  35 in total

Review 1.  Targeting NOX enzymes in the central nervous system: therapeutic opportunities.

Authors:  Silvia Sorce; Karl-Heinz Krause; Vincent Jaquet
Journal:  Cell Mol Life Sci       Date:  2012-05-30       Impact factor: 9.261

Review 2.  NOX Modifiers-Just a Step Away from Application in the Therapy of Airway Inflammation?

Authors:  Joanna Wieczfinska; Milena Sokolowska; Rafal Pawliczak
Journal:  Antioxid Redox Signal       Date:  2014-02-19       Impact factor: 8.401

Review 3.  Diabetes and Kidney Disease: Role of Oxidative Stress.

Authors:  Jay C Jha; Claudine Banal; Bryna S M Chow; Mark E Cooper; Karin Jandeleit-Dahm
Journal:  Antioxid Redox Signal       Date:  2016-04-01       Impact factor: 8.401

Review 4.  Therapeutic potential of NADPH oxidase 1/4 inhibitors.

Authors:  G Teixeira; C Szyndralewiez; S Molango; S Carnesecchi; F Heitz; P Wiesel; J M Wood
Journal:  Br J Pharmacol       Date:  2016-07-14       Impact factor: 8.739

Review 5.  Nox Inhibitors & Therapies: Rational Design of Peptidic and Small Molecule Inhibitors.

Authors:  M Eugenia Cifuentes-Pagano; Daniel N Meijles; Patrick J Pagano
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

6.  Inhibiting the Activity of NADPH Oxidase in Cancer.

Authors:  Mariam M Konaté; Smitha Antony; James H Doroshow
Journal:  Antioxid Redox Signal       Date:  2020-04-17       Impact factor: 8.401

Review 7.  Redox-based therapeutics in neurodegenerative disease.

Authors:  G J McBean; M G López; F K Wallner
Journal:  Br J Pharmacol       Date:  2016-08-25       Impact factor: 8.739

8.  Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo.

Authors:  Joy X Jiang; Xiangling Chen; Nobuko Serizawa; Cédric Szyndralewiez; Patrick Page; Katrin Schröder; Ralf P Brandes; Sridevi Devaraj; Natalie J Török
Journal:  Free Radic Biol Med       Date:  2012-05-19       Impact factor: 7.376

Review 9.  NADPH oxidases in lung health and disease.

Authors:  Karen Bernard; Louise Hecker; Tracy R Luckhardt; Guangjie Cheng; Victor J Thannickal
Journal:  Antioxid Redox Signal       Date:  2014-01-03       Impact factor: 8.401

Review 10.  Nox4 and diabetic nephropathy: with a friend like this, who needs enemies?

Authors:  Yves Gorin; Karen Block
Journal:  Free Radic Biol Med       Date:  2013-03-23       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.